18F-DOPA II - PET imaging optimization
Brain Metastases | Parkinson Disease | Congenital Hyperinsulinism | Neuroblastoma | Brain Tumor | Neuroendocrine...The primary purpose of this study is to allow appropriate patients access to F-DOPA PET imaging and to assess improvements in our imaging technique.
Participation in this study allows access to FDOPA PET scans for specific patient groups including:
1. Pediatric patients (<18 years old) with congenital hyperinsulinism.
2. Pediatric patients (<18 years old) with neuroblastoma.
3. Pediatric (l<18 years old) or Adult patients (18 or older) with known or clinically suspected neuroendocrine tumor.
4. Adult patients (18 or older) with a clinical suspicion of Parkinson's disease or Lewy body dementia.
5. Pediatric (<18 years old) or Adult patients (18 or older) with brain tumors.
null
Participation Requirements
-
Sex:
Any -
Eligible Ages:
0 and up
Participation Criteria
Inclusion Criteria:
1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism.
2. Pediatric patients (less than 18 years old) with neuroblastoma.
3. Pediatric (less than 18 years old) or Adult patients (18 or older) with known or clinically suspected neuroendocrine tumor.
4. Adult patients (18 or older) with a clinical suspicion of Parkinson's disease or Lewy body dementia.
5. Pediatric (less than 18 years old) or Adult patients (18 or older) with brain tumors.
Exclusion Criteria:
1. Unable to obtain consent
2. Weight >225 kg (weight limitation of PET/CT scanner)
3. Adult patients unable to lie flat for 20-30 minutes to complete the PET-CT session.
4. Young pediatric patients (less than 13 years old) who are unable to lie flat for 20-30 minutes and for whom clinical sedation is contraindicated (as determined by a pediatric anaesthesiologist).
5. Lack of intravenous access
Study Location
University of Alberta
University of AlbertaEdmonton, Alberta
Canada
Contact Study Team
- Study Sponsored By
- University of Alberta
- Participants Required
- More Information
- Study ID:
Pro00100294